TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00069108
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As prescribed, in 2 week cycles
Study: NCT00069108
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 po bid on days 1-15 of each 3 week cycle
Study: NCT04617561
Drug: Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
Study: NCT01093261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days.
Study: NCT00580645
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00682890
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo birth control pill daily
Study: NCT00069719
Drug: Glaucoma therapy
Normalized name: Sympathomimetics in glaucoma therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00414414
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04259515
Drug: Del Nido
Normalized name: Del Nido Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
Study: NCT04259515
Drug: Buckberg
Normalized name: ISOPROPYL ALCOHOL 80 mL in 100 mL TOPICAL GEL [Buckler Signature Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
Study: NCT02212210
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00326404
Drug: Desogestrel-Ethinyl Estradiol 21 tablets
Normalized name: desogestrel / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
Study: NCT00326404
Drug: Desogestrel-Ethinyl Estradiol 28 tablets
Normalized name: desogestrel / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
Study: NCT04602221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Film-coated tablet
Study: NCT03118986
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
Study: NCT00819390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally, once daily for 12 weeks.
Study: NCT02187627
Drug: [11C]RO6924963
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\].
Study: NCT03182218
Drug: Direct oral anticoagulant
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
Study: NCT01191268
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01222026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1000mg Calcium 800 IE Vitamin-D
Study: NCT02058654
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine powder (5 g)
Study: NCT02058654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulking agent powder (5 g)
Study: NCT04641871
Drug: Sym021
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Study: NCT04641871
Drug: Sym022
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Study: NCT04641871
Drug: Sym023
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Study: NCT01386073
Drug: FreshKote
Normalized name: FreshKote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times a day for three months
Study: NCT00986973
Drug: Sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
Study: NCT01536418
Drug: GSK1605786A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 milligrams twice daily, orally adminstered for 12 weeks
Study: NCT03390647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6130-matched placebo
Study: NCT00577837
Drug: experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, 200 mg risedronate monthly for 6 months
Study: NCT04486326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00888004
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00888004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02434497
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
Study: NCT00619203
Drug: Glycerol and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7
Study: NCT00619203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebos, one po, one suppository
Study: NCT00619203
Drug: Paracetamol and glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses
Study: NCT01535560
Drug: AL-60371, 0.3% otic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational otic suspension intended for the treatment of acute otitis externa
Study: NCT03432221
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
Study: NCT01688830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01304433
Drug: Venofundin 6% / Tetraspan 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venofundin 6% / Tetraspan 6%
Study: NCT01957449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months.
Study: NCT00505284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, once daily, for 15 weeks (taken orally).
Study: NCT00505284
Drug: E2007 (2 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel, 2 mg once daily, for 15 weeks (taken orally).
Study: NCT00505284
Drug: E2007 (4 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
Study: NCT00505284
Drug: E2007 (6 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
Study: NCT00505284
Drug: E2007 (8 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
Study: NCT02515435
Drug: apatinib single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
Study: NCT02872246
Drug: BAY 987516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT00252785
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01981395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
Study: NCT00002570
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
Study: NCT00002570
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg/m2 IV - number of cycles is determined by patient and physician
Study: NCT02403674
Drug: ATRIPLA™
Approvals — FDA: no, EMA: no, PMDA: no
Description: One ATRIPLA™ tablet taken q.d. by mouth
Study: NCT02403674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
Study: NCT00126204
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02297503
Drug: Azzalure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glabellar lines
Study: NCT00353054
Drug: Caltrate® 600 + D
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00025103
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025103
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02463110
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02463110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03930186
Drug: Topical Therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
Study: NCT01418092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT00021398
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00021398
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02895035
Drug: Phenylephrine-ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
Study: NCT02895035
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
Study: NCT03154086
Drug: GSK3352589
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
Study: NCT03154086
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be available across all strengths to match active drug in the form of tablet for oral administration.
Study: NCT01992952
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
Study: NCT01992952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
Study: NCT03844906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with Ketamine
Study: NCT03575702
Drug: Uritos®
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablets 0.1 mg
Study: NCT03575702
Drug: Urotol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: film coated tablets, 2 mg
Study: NCT01049217
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
Study: NCT02224014
Drug: Lendormin D tablets
Normalized name: D-biotin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02872246
Drug: SPF 15 Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT01685671
Drug: NESP 60μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated NESP 60μg once subcutaneously
Study: NCT01685671
Drug: CKD-11101 60μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated CKD-11101 60μg once subcutaneously
Study: NCT01381393
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT00539773
Drug: BCG, Interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT01744496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches match the size of active patches 20 cm\^2, 30 cm\^2, or 40 cm\^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
Study: NCT00278564
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02775695
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
Study: NCT00141102
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are assigned to one of two groups in parallel for the duration of the study
Study: NCT04308161
Drug: BBC oral spray
Normalized name: SNAIL, UNSPECIFIED 18.05 g in 40 g / TITANIUM DIOXIDE 3.6 g in 40 g / ZINC OXIDE 2.52 g in 40 g / ARBUTIN 0.8 g in 40 g / ADENOSINE 0.016 g in 40 g TOPICAL CREAM [SKIN79 SNAIL NUTRITION BBCREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetics and anti-inflammatory agent
Study: NCT04308161
Drug: Oracure gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesic gel
Study: NCT02347046
Drug: FYU-981, (Oral single dosing)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FYU-981, (Oral single dosing)
Study: NCT02682745
Drug: TALION tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration
Study: NCT00513643
Drug: human regular insulin
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6, 12 and 24 IU sc
Study: NCT03301896
Drug: LHC165
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHC165 intratumoral injection
Study: NCT01781507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This placebo ( sugar pill) will provide the negative control for this study
Study: NCT00503828
Drug: Derris scandens Benth extracts
Normalized name: Senecio scandens flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
Study: NCT00503828
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg/day for 4 weeks
Study: NCT01108939
Drug: Antimalarial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03504917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo.
Study: NCT00822523
Drug: Botulinum Toxin, Type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 units, single dose, intramuscular in right EDB muscle
Study: NCT00822523
Drug: Botulinum Toxin, Type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 units, single dose, intramuscular to right EDB muscle
Study: NCT00141102
Drug: Diclofenac + Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are assigned to one of two groups in parallel for the duration of the study
Study: NCT01000285
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01300962
Drug: BMK120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
Study: NCT01300962
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
Study: NCT01300962
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
Study: NCT01598311
Drug: CB-183,315
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
Study: NCT01598311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo size 00 opaque hard gelatin capsules.
Study: NCT05380778
Drug: Deep anesthesia
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45
Study: NCT05380778
Drug: Shallow anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45
Study: NCT04308343
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drugs to treat undisturbed ectopic pregnancies
Study: NCT01372423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mcg capsules
Study: NCT00691028
Drug: TA-650 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Study: NCT00691028
Drug: TA-650 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Study: NCT00691028
Drug: TA-650 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.